Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,055Revenue (TTM) $M159Net Margin (%)-23.3Altman Z-Score1.2
Enterprise Value $M1,012EPS (TTM) $-0.3Operating Margin %-18.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-1.1Pre-tax Margin (%)-23.3Higher ROA y-yY
Price/Book35.910-y EBITDA Growth Rate %1.4Quick Ratio4.5Cash flow > EarningsY
Price/Sales6.65-y EBITDA Growth Rate %-4.9Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-18.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-96.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M129ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOFirst Eagle Investment 2016-03-31 Add0.06%$7.17 - $17.33
($9.52)
$ 8.02-16%Add 54.76%6,663,700
HALOFirst Eagle Investment 2015-12-31 Add0.01%$12.93 - $18.59
($16.02)
$ 8.02-50%Add 6.10%4,305,900
HALOJoel Greenblatt 2015-12-31 Sold Out $12.93 - $18.59
($16.02)
$ 8.02-50%Sold Out0
HALOFirst Eagle Investment 2015-09-30 Reduce-0.01%$13.25 - $24.75
($20.12)
$ 8.02-60%Reduce -2.49%4,058,500
HALOJoel Greenblatt 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 8.02-60%Reduce -21.11%28,955
HALOKen Fisher 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 8.02-60%Reduce -4.48%707,780
HALOFirst Eagle Investment 2015-06-30 Add0.02%$14.28 - $22.58
($17.52)
$ 8.02-54%Add 8.55%4,162,000
HALOJoel Greenblatt 2015-06-30 Buy 0.01%$14.28 - $22.58
($17.52)
$ 8.02-54%New holding36,701
HALOKen Fisher 2015-06-30 Reduce$14.28 - $22.58
($17.52)
$ 8.02-54%Reduce -2.86%740,955
HALOFirst Eagle Investment 2015-03-31 Reduce$9.82 - $16.2
($14.42)
$ 8.02-44%Reduce -3.92%3,834,050
HALOFirst Eagle Investment 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 8.02-16%Add 30.25%3,640,480
HALOFirst Eagle Investment 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 8.02-5%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 8.02-5%New holding791,760
HALOFirst Eagle Investment 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 8.02-38%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 8.02-2%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 8.0221%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-52.61view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-52.61view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-61.1view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-46.71view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.9-8.2view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.92-8.41view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-17.97view
Engler RobertDirector 2014-08-14Sell35,000$9.96-17.97view
Engler RobertDirector 2014-05-15Sell126,700$7.568.07view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.13-10.51view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
The Quest for an Effective Treatment for Pancreatic Cancer Jun 22 2016
ETF’s with exposure to Halozyme Therapeutics, Inc. : June 10, 2016 Jun 10 2016
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance Jun 08 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 08 2016
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance Jun 08 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June... Jun 06 2016
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic... Jun 04 2016
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic... Jun 04 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : May... May 26 2016
HALOZYME THERAPEUTICS INC Financials May 18 2016
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference May 17 2016
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference May 17 2016
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Edited Transcript of HALO earnings conference call or presentation 9-May-16 8:30pm GMT May 09 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition May 09 2016
Halozyme Therapeutics reports 1Q loss May 09 2016
Halozyme Therapeutics reports 1Q loss May 09 2016
Halozyme Reports First Quarter 2016 Financial Results May 09 2016
Halozyme Reports First Quarter 2016 Financial Results May 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)